COST-EFFECTIVENESS OF BETA BLOCKERS AND THE SURVIVAL OF THE PATIENTS WITH HEART FAILURE IN THE CARDIOLOGY CENTER IN TIRANA

Authors

  • MIRELA MIRACI Faculty of Pharmacy, University of Medicine, Tirana. Albania
  • Mimoza Lezha University Hospital Centre, Department of Cardiology and Blood Vessel Disease, Tirana, Albania
  • Indrit Temali University Hospital Centre, Department of Cardiology and Blood Vessel Disease, Tirana, Albania
  • Linda Matua Faculty of Pharmacy, University of Medicine, Tirana. Albania
  • Vilma Papajani Faculty of Pharmacy, University of Medicine, Tirana. Albania
  • Elizana Petrela Faculty of Public Health, University of Medicine, Tirana, Albania

Keywords:

Chronic heart failure, Carvedilol, Metoprolol, Survival rate

Abstract

Objective: To evaluate the survival of the patients with heart failure in the Cardiology Center in Tirana, to evaluate the cost effectiveness of carvedilol versus metoprolol.

Methods: 239 patients (pts) suffering chronic heart failure of different aetiologies, on traditional treatment for heart failure (angiotensin-converting enzyme inhibitors, diuretics, digoxin), with ejection fraction<50%, in NYHA class II-IV, were randomised to carvedilol 6.25-25 mg/day, or metoprolol 50-100 mg/day, or nebivolol 5 mg/day or treated only with the traditional treatment for they have contraindications regarding the use of β–blockers, followed for a two-year period.

Results: There were included 239 patients of mild, moderate and severe heart failure, NYHA II-IV, with the fraction of ejection<50 hospitalized in the University clinic of cardiology of Tirana, followed for a two-year period; 83 patients (34.7%) were treated with Carvedilol; 70 patients (29.2%) were treated with metoprolol, 21 patients were treated with nebivolol (8.7%), and 65 patients (27.1%) were treated only with the traditional therapy (TTh).

Conclusion: The use of carvedilol along with the traditional therapy of heart failure assures a higher survival rate and a lower hospitalization rate but an increase of cost of treatment of 216 €a year compared to metoprolol in addition with traditional therapy.

 

Downloads

Download data is not yet available.

References

REFERENCES

Packer M, Bristow MR, Cohn JN, Colucci WS, Fowler MB, Gilbert EM,Shusterman NH, The effect of carvedilol on morbidity and mortality in patients with chronic heart failure, US Carvedilol Heart Failure Study Group, The New England Journal of Medicine 1996;334:1349–1355,

Packer M, Coats AJ, Fowler MB, Katus HA, Krum H, et al, Carvedilol Prospective Randomized Cumulative Survival Study Group, Effect of carvedilol on survival in severe chronic heart failure, The New England Journal of Medicine 2001;344:1651–1658

MERIT-CHF Study Group, Effect of metoprolol CR/XL in chronic heart failure: Metoprolol CR/XL Randomised Intervention Trial in Congestive Heart Failure (MERIT-CHF), Lancet 1999;353:2001–2007,

Poole-Wilson P,A,, Swedberg K,, Cleland J,G,F,, et al, Comparison of carvedilol and metoprolol on clinical outcomes in patients with chronic heart failure in the Carvedilol Or Metoprolol European Trial (COMET): randomised controlled trial, Lancet 2003;362:7-13,

CIBIS-II Investigators and Committees, The Cardiac Insufï¬ciency Bisoprolol Study II (CIBIS-II): a randomised trial, Lancet 1999;353:9–13,

Bristow MR, Beta-adrenergic receptor blockade in chronic heart failure,Circulation 2000;101:558–569,

Metra M, Nodari S, D’Aloia A, Bontempi L, Boldi E, Dei Cas L, A rationale for the use of beta-blockers as standard treatment for heart failure, American Heart Journal 2000;139:511–521,

Azevedo E,R,, Kubo T,, Mak S, Nonselective versus selective β-adrenergic receptor blockade in congestive heart failure, Differential effects on sympathetic activity, Circulation 2001;104:2194-2199,

Gilbert E,M, Abraham W,T,, Olsen S,, et al , Comparative hemodynamic, left ventricular functional, and antiadrenergic effects of chronic treatment with metoprolol versus carvedilol in the failing heart, Circulation 1996;94:2817-2825,

Kurz T,, Richardt D,, Gorge B,, et al , Differential effects of carvedilol on norepinephrine release in normoxic and ischemic heart, Journal of Cardiovascular Pharmacology 2000;36:96-100,

Kindermann M,, Maack C,, Schaller S,, et al, Carvedilol but not metoprolol reduces β-adrenergic responsiveness after complete elimination from plasma in vivo, Circulation 2004;109:3182-3189,

Allison P,D, - 1982, Discrete Time Methods in the Analysis of Event Historiesâ€, in Leinhardt S,, Sociological Methodology 1982, San Francisco, Jossey-Bass,

Allison P,D, - 1984, Event History Analysis, Regression for Longitudinal Event Data, Sage, Newbury Park, CA,

Allison P,D, - 1995, Survival analysis using the SAS System, A practical guide, SAS Institute, USA,

Cleves M,A,, Gould W,W, and Gutierrez R,G, - 2002, An Introduction to Survival Analysis using STATA, STATA Press, Texas,

Collett D,, - 1994, Modelling Survival data in Medical Research, Chapman & Hall, London,

Cox D,R, – 1972, Regression models and life-tables (with discussion), Journal of the Royal Statistics Society, Series B 30: 248-275,

Gjonca A,, Tomasini C dhe Vaupel JW - (1999) "Pourqui les femmes survivent aux hommes1. Packer M, Bristow MR, Cohn JN, Colucci WS, Fowler MB, Gilbert EM, et al. The effect of carvedilol on morbidity and mortality in patients with chronic heart failure. US Carvedilol Heart Failure Study Group. N Engl J Med 1996;334:1349–55.

Packer M, Coats AJ, Fowler MB, Katus HA, Krum H. Carvedilol prospective randomized cumulative survival study group, Effect of carvedilol on survival in severe chronic heart failure. N Engl J Med 2001;344:1651–8.

MERIT-CHF Study Group. Effect of metoprolol CR/XL in chronic heart failure: Metoprolol CR/XL Randomised Intervention Trial in Congestive Heart Failure (MERIT-CHF). Lancet 1999;353:2001–7.

Poole-Wilson PA, Swedberg K, Cleland JGF. Comparison of carvedilol and metoprolol on clinical outcomes in patients with chronic heart failure in the carvedilol or metoprolol european trial (COMET): randomized controlled trial. Lancet 2003;362:7-13.

CIBIS-II Investigators and Committees, The Cardiac Insufï¬ciency Bisoprolol Study II (CIBIS-II): a randomised trial. Lancet 1999;353:9–13.

Bristow MR. Beta-adrenergic receptor blockade in chronic heart failure. Circulation 2000;101:558–69.

Metra M, Nodari S, D’Aloia A, Bontempi L, Boldi E, Dei Cas L. A rationale for the use of beta-blockers as standard treatment for heart failure. Am Heart J 2000;139:511–21.

Azevedo ER, Kubo T, Mak S. Nonselective versus selective β-adrenergic receptor blockade in congestive heart failure, Differential effects on sympathetic activity. Circulation 2001;104:2194-9.

Gilbert EM, Abraham WT, Olsen S. Comparative hemodynamic, left ventricular functional, and antiadrenergic effects of chronic treatment with metoprolol versus carvedilol in the failing heart. Circulation 1996;94:2817-25.

Kurz T, Richardt D, Gorge B. Differential effects of carvedilol on norepinephrine release in normoxic and ischemic heart. J Cardiovasc Pharmacol 2000;36:96-100.

Kindermann M, Maack C, Schaller S. Carvedilol but not metoprolol reduces β-adrenergic responsiveness after complete elimination from plasma in vivo. Circulation 2004;109:3182-9.

C Theivarasu, Santanu Ghosh, T Indumathi. Uv Spectrophotometric determination of carvedilol in pharmaceutical formulations. Asian J Pharm Clin Res 2010;3:4.

Allison PD. Discrete time methods in the analysis of event historiesâ€. In Leinhardt S, Sociological Methodology 1982, San Francisco, Jossey-Bass; 1982.

Allison PD. Event history analysis, Regression for longitudinal event data, Sage, Newbury Park, CA; 1984.

Allison PD. Survival analysis using the SAS System, A practical guide, SAS Institute, USA; 1995.

Cleves MA, Gould WW, Gutierrez RG. An introduction to survival analysis using STATA, STATA Press: Texas; 2002.

Collett D. Modelling survival data in medical research, Chapman & Hall, London; 1994.

Cox DR. Regression models and life-tables (with discussion). J Royal Statistics Soc 1972;Series B30:248-75,

Gjonca A, Tomasini C, dhe Vaupel JW. "Pourqui les femmes survivent aux hommes?" in La Recherche, Special Issue: "To live 120 years", Nr.322 Julliet/Août 1999. p. 96-9.

Waagstein F, Bristow MR, Swedberg K. Beneficial effects of metoprolol in idiopathic dilated cardiomyopathy. Lancet 1993;342:1441-6.

CIBIS Investigators and Committees. A randomized trial of β-blockade in heart failure: the cardiac insufficiency bisoprolol study (CIBIS). Circulation 1994;90:1765-73.

?" in La Recherche, Special Issue: "To live 120 years", N,322 Julliet/Août pp,96-99,

Waagstein F, Bristow MR, Swedberg K, et al. Beneficial effects of metoprolol in idiopathic dilated cardiomyopathy. Lancet 1993;342:1441-1446

CIBIS Investigators and Committees. A randomized trial of β-blockade in heart failure: the Cardiac Insufficiency Bisoprolol Study (CIBIS). Circulation 1994;90:1765-1773

Published

01-07-2015

How to Cite

MIRACI, M., M. Lezha, I. Temali, L. Matua, V. Papajani, and E. Petrela. “COST-EFFECTIVENESS OF BETA BLOCKERS AND THE SURVIVAL OF THE PATIENTS WITH HEART FAILURE IN THE CARDIOLOGY CENTER IN TIRANA”. International Journal of Pharmacy and Pharmaceutical Sciences, vol. 7, no. 7, July 2015, pp. 261-4, https://www.innovareacademics.in/journals/index.php/ijpps/article/view/6250.

Issue

Section

Original Article(s)